Online inquiry

IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8608MR)

This product GTTS-WQ8608MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8608MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10430MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ575MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ2630MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ5480MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ2716MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ1316MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ12650MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ13266MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06252616
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW